

Polyenolate-mediated reaction cascade initiated by the higher-order-cycloaddition for the construction of polycarbocyclic scaffold

Adam Cieśliński,^a Anna Skrzyńska,^a Artur Przydacz^a and Łukasz Albrecht^{a*}

^aInstitute of Organic Chemistry

Faculty of Chemistry

Lodz University of Technology

Żeromskiego 116, 90-924 Łódź, Poland

e-mail: lukasz.albrecht@p.lodz.pl

Contents

1. General methods	S3
2. Synthesis of 2-((1 <i>H</i> -inden-2-yl)methylene)malononitriles 1 - general procedure	S4
3. Polyenolate-mediated reaction cascade initiated by the higher-order-cycloaddition – general procedure	S8
4. Enantioselective synthesis of (<i>3S,4aS,9bR,10R,10aR</i>)-2-formyl-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3 <i>H</i>)-dicarbonitrile 3a on a 1 mmol scale	S19
5. Selective transformations of products 3	S20
6. Crystal and X-ray data for (<i>3S,4aS,9bS,10R,10aR</i>)-9-bromo-2-formyl-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3 <i>H</i>)-dicarbonitrile 3m	S22
7. NMR Spectra	S24
8. UPC ² Traces	S58


1. General methods

NMR spectra were acquired on a Bruker Ultra Shield 700 instrument, running at 700 MHz for ¹H and 176 MHz for ¹³C, respectively or on a Jeol 400YH instrument, running at 376 MHz for ¹⁹F. Chemical shifts (δ) are reported in ppm relative to residual solvent signals (CDCl₃: 7.26 ppm for ¹H NMR, 77.16 ppm for ¹³C NMR). Chemical shifts (δ) for ¹⁹F NMR are reported in ppm relative to C₆H₅CF₃ (trifluorotoluene) as external reference. High-resolution mass spectra (HRMS) were obtained on Bruker ESI-Q-TOF Impact II spectrometer using electrospray (ESI+) ionization. Analytical thin layer chromatography (TLC) was performed using pre-coated aluminum-backed plates (Merck Kieselgel 60 F254) and visualized by ultraviolet irradiation or Hanessian's stain. Unless otherwise noted, analytical grade solvents and commercially available reagents were used without further purification. For flash chromatography (FC) silica gel (Silica gel 60, 230-400 mesh, Fluka). The enantiomeric ratio (er) of the products were determined by Ultra Performance Convergence Chromatography (UPC²) using Daicel Chiralpak IA, IB, IC, IG columns as chiral stationary phases. Indene-2-carbaldehydes used for the synthesis of the corresponding malononitriles **1** were synthesized according to the literature procedure¹. Aldehydes **2** were prepared from the corresponding starting materials following the literature procedure.²

¹ B. S. Donslund, N. I. Jessen, G. Bertuzzi, M. Giardinetti, T. A. Palazzo, M. Louise Christensen, K. A. Jørgensen, *Angew. Chem., Int. Ed.* 2018, **57**, 13182–13186.


² N. Daubresse, C. Francesch, C. Rolando, *Tetrahedron* 1998, **54**, 10761-10770.

2. Synthesis of 2-((1*H*-inden-2-yl)methylene)malononitriles **1** - general procedure




In a flame-dried round-bottom flask equipped with a magnetic stirring bar the corresponding indene-2-carbaldehyde (3 mmol, 1.0 equiv.), malononitrile (3.6 mmol, 1.2 equiv.) and benzoic acid (0.6 mmol, 0.2 equiv.) were dissolved in toluene (18 ml, 0.16 M) and piperidine (0.6 mmol, 0.2 equiv.) was added. The reaction mixture was refluxed for 1 hour. After full conversion of the starting indene-2-carbaldehyde (as confirmed by TLC analysis), mixture was cooled to rt and diluted with Et₂O (20 mL) and washed with water (2×15 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting solid was subjected to column chromatography on silica gel (eluent: petroleum ether: dichloromethane 40:60) to afford pure product **1**.


2-((3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1a**

 Following the general procedure product **1a** was isolated in 82% yield (660.2 mg) as light-orange solid; mp = 180 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.67 (s, 1H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.61 – 7.56 (m, 3H), 7.53 – 7.48 (m, 2H), 7.43 – 7.39 (m, 3H), 4.19 (s, 2H). ¹³C NMR (176 MHz, CDCl₃) δ 161.6, 153.0, 145.1, 142.6, 135.6, 132.1, 130.5, 130.2, 129.6 (2C), 129.3 (2C), 127.8, 124.9, 124.1, 115.1, 114.1, 78.8, 38.0. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₁₉H₁₃N₂⁺: 269.1073; found: 269.1070.

2-((5-methoxy-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1b**


 Following the general procedure product **1b** was isolated in 80% yield (715.0 mg) as brown solid; mp = 188 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.63 (s, 1H), 7.61 – 7.56 (m, 3H), 7.53 (d, *J* = 8.3 Hz, 1H), 7.40 – 7.37 (m, 2H), 7.08 (dd, *J* = 8.3, 2.4 Hz, 1H), 6.95 (d, *J* = 2.4 Hz, 1H), 4.11 (s, 2H), 3.80 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 161.4, 159.8, 152.9, 143.9, 137.5, 136.8, 132.1, 130.1, 129.6 (2C), 129.4 (2C), 125.5, 117.8, 115.1, 114.1, 108.1, 78.7, 55.8, 37.3. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₂₀H₁₅N₂O⁺: 299.1179; found: 299.1172.

2-((6-methoxy-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1c**




Following the general procedure product **1c** was isolated in 88% yield (786.7 mg) as brown solid; mp = 192 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.61 – 7.54 (m, 4H), 7.41 – 7.36 (m, 3H), 7.18 (d, *J* = 2.0 Hz, 1H), 6.95 (dd, *J* = 8.6, 2.3 Hz, 1H), 4.14 (s, 2H), 3.91 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 162.7, 161.9, 152.6, 148.1, 135.9, 133.8, 132.3, 130.1, 129.6 (2C), 129.3 (2C), 125.4, 115.6, 115.0, 114.7, 109.9, 76.3, 55.9, 37.9. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₂₀H₁₅N₂O⁺: 299.1179; found: 299.1169.

2-((5-methyl-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1d**




Following the general procedure product **1d** was isolated in 97% yield (820.1 mg) as light-yellow solid; mp = 196 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.65 (s, 1H), 7.63 – 7.56 (m, 3H), 7.53 (d, *J* = 7.7 Hz, 1H), 7.40 (dt, *J* = 4.2, 2.3 Hz, 2H), 7.33 (dd, *J* = 7.7, 0.7 Hz, 1H), 7.28 (d, *J* = 0.6 Hz, 1H), 4.13 (s, 2H), 2.41 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 161.7, 153.0, 142.9, 142.4, 137.7, 135.9, 132.2, 131.7, 130.1, 129.6 (2C), 129.3 (2C), 124.6, 124.4, 115.2, 114.2, 78.4, 37.6, 21.5. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₂₀H₁₅N₂⁺: 283.1230; found: 283.1224.

2-((6-bromo-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1e**



Following the general procedure product **1e** was isolated in 78% yield (812.0 mg) as dark yellow solid; mp = 198 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.79 (d, *J* = 1.0 Hz, 1H), 7.64 (s, 1H), 7.62 – 7.56 (m, 3H), 7.54 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.39 – 7.35 (m, 2H), 7.33 (d, *J* = 8.2 Hz, 1H), 4.15 (s, 2H). ¹³C NMR (176 MHz, CDCl₃) δ 160.5, 152.7, 146.5, 141.6, 135.5, 131.6, 131.2, 130.4, 129.6 (2C), 129.5 (2C), 128.2, 125.3, 125.0, 114.9, 114.0, 79.6, 37.8. HRMS (ESI) m/z [M-H]⁻ Calcd. for C₁₉H₁₀BrN₂⁻: 345.0033; found: 345.0036.


2-((7-bromo-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1f**



Following the general procedure product **1f** was isolated in 64 % yield (666.2 mg) as dark yellow solid; mp = 204 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.66 (s, 1H), 7.63 (dd, *J* = 7.9, 0.7 Hz, 1H), 7.62 – 7.57 (m, 3H), 7.44 (dd, *J* = 7.7, 0.7 Hz, 1H), 7.40 – 7.37 (m, 2H), 7.30 (t, *J* = 7.8 Hz, 1H), 4.14 (s, 2H). ¹³C NMR (176 MHz, CDCl₃) δ 160.7, 152.6, 144.9, 144.0, 135.6, 133.2, 131.8, 130.4, 129.6 (2C), 129.5, 129.4 (2C),


123.0, 119.8, 114.8, 113.6, 80.3, 39.5. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₁₉H₁₂BrN₂⁺: 347.0179; found: 347.0176.

2-((3-(4-methoxyphenyl)-1*H*-inden-2-yl)methylene)malononitrile **1g**




Following the general procedure product **1g** was isolated in 80% yield (715.2 mg) as red solid; mp = 158 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.68 (s, 1H), 7.64 (d, *J* = 7.5 Hz, 1H), 7.53 (d, *J* = 7.7 Hz, 1H), 7.51 – 7.48 (m, 1H), 7.41 (t, *J* = 7.5 Hz, 1H), 7.38 – 7.34 (m, 2H), 7.14 – 7.09 (m, 2H), 4.16 (s, 2H), 3.92 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 161.5, 161.3, 153.2, 145.2, 142.7, 135.0, 131.3 (2C), 130.4, 127.7, 124.9, 124.4, 124.1, 115.3, 114.9 (2C), 114.3, 78.1, 55.6, 37.9. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₂₀H₁₅N₂O⁺: 299.1179; found: 299.1170.

2-((3-(4-fluorophenyl)-1*H*-inden-2-yl)methylene)malononitrile **1h**




Following the general procedure product **1h** was isolated in 81% yield (696 mg) as light-yellow solid; mp = 184°C. ¹H NMR (700 MHz, CDCl₃) δ 7.66 (d, *J* = 7.6 Hz, 1H), 7.62 (s, 1H), 7.52 (td, *J* = 7.4, 1.2 Hz, 1H), 7.46 (d, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 7.6 Hz, 1H), 7.41 – 7.39 (m, 2H), 7.32 – 7.28 (m, 2H), 4.18 (s, *J* = 46.5 Hz, 2H). ¹³C NMR (176 MHz, CDCl₃) δ 163.8 (d, *J* = 251.5 Hz), 160.3, 152.6, 145.0, 142.5, 135.8, 131.6 (d, *J* = 8.5 Hz) (2C), 130.7, 128.1 (d, *J* = 3.5 Hz), 127.9, 125.0, 123.8, 116.67 (d, *J* = 21.8 Hz) (2C), 115.0, 114.0, 79.2, 38.0. ¹⁹F NMR (376 MHz, CDCl₃) δ -109.6. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₁₉H₁₂FN₂⁺: 287.0979; found: 287.0974.

2-((3-([1,1'-biphenyl]-4-yl)-1*H*-inden-2-yl)methylene)malononitrile **1i**




Following the general procedure product **1i** was isolated in 78% yield (804.9 mg) as light-yellow solid; mp = 240 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.83 – 7.80 (m, 2H), 7.74 (s, 1H), 7.71 – 7.66 (m, 3H), 7.57 (d, *J* = 7.7 Hz, 1H), 7.54 – 7.51 (m, 3H), 7.50 – 7.48 (m, 2H), 7.44 (t, *J* = 7.4 Hz, 2H), 4.21 (s, 2H). ¹³C NMR (176 MHz, CDCl₃) δ 161.1, 152.9, 145.1, 143.1, 142.5, 139.9, 135.5, 130.8, 130.5, 130.1 (2C), 129.1 (2C), 128.1, 127.9 (2C), 127.7, 127.2 (2C), 124.9, 124.0, 115.0, 114.1, 78.7, 38.0. HRMS (ESI) m/z [M+Na]⁺ Calcd. for C₂₅H₁₆N₂Na⁺: 367.1206; found: 367.1199.

2-((3-(5-methylthiophen-2-yl)-1*H*-inden-2-yl)methylene)malononitrile **1j**




Following the general procedure product **1j** was isolated in 87% yield (751.7 mg) as orange solid; mp = 191 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.96 (s, 1H), 7.83 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 7.5 Hz, 1H), 7.50 (td, *J* = 7.4, 1.1 Hz, 1H), 7.44 (t, *J* = 7.5 Hz, 1H), 7.14 (d, *J* = 3.5 Hz, 1H), 7.00 – 6.95 (m, 1H), 4.14 (s, 2H), 2.64 (d, *J* = 0.6 Hz, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 153.2, 152.8, 145.8, 145.0, 141.8, 135.2, 131.4, 130.5, 130.5, 127.8, 127.1, 124.9, 124.2, 115.4, 114.3, 78.4, 38.0, 15.7. HRMS (ESI) m/z [M+Na]⁺ Calcd. for C₁₈H₁₂N₂Na⁺: 311.0614; found: 311.0619.

2-((1*H*-inden-2-yl)methylene)malononitrile **1k**




Following the general procedure product **1k** was isolated in 46% yield (265.0 mg) as orange solid; mp = 175 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.75 (s, 1H), 7.65 (s, 1H), 7.60 (d, *J* = 7.6 Hz, 1H), 7.58 (d, *J* = 7.5 Hz, 1H), 7.46 (td, *J* = 7.5, 1.1 Hz, 1H), 7.41 (t, *J* = 7.4 Hz, 1H), 4.00 (s, 2H). ¹³C NMR (176 MHz, CDCl₃) δ 153.9, 150.0, 145.9, 141.7, 140.7, 130.2, 127.9, 124.8, 124.5, 114.5, 113.6, 79.7, 37.9. HRMS (ESI) m/z [M+H]⁺ Calcd. for C₁₃H₉N₂⁺: 193.0760; found: 193.0762.

3. Polyenolate-mediated reaction cascade initiated by the higher-order-cycloaddition - general procedure




In an ordinary 4 mL glass vial equipped with a magnetic stirring, corresponding malononitrile **1** (0.2 mmol), α,β -unsaturated aldehyde **2** (0.2 mmol) and *R*-mandelic acid (0.04 mmol) were dissolved in DCE (0.4 mL) and catalyst **4a** (6.6 mg, 0.02 mmol) was added. The reaction mixture was stirred in room temperature for the indicated time. The progress of the reaction was controlled by ^1H NMR spectroscopy. After full conversion of the starting material **1**, the reaction mixture was directly subjected to column chromatography on silica gel (hexanes: ethyl acetate 80:20) to afford pure product **3**.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-a]indene-4,4(3*H*)-dicarbonitrile 3a




Following the general procedure product **3a** (>20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 65% yield (33.4 mg) as yellow solid; mp = 226 °C. ^1H NMR (700 MHz, CDCl_3) δ 9.35 (s, 1H), 7.57 (d, J = 4.8 Hz, 4H), 7.51 – 7.46 (m, 2H), 7.44 (t, J = 7.3 Hz, 2H), 7.28 (d, J = 7.3 Hz, 2H), 7.25 (d, J = 7.3 Hz, 1H), 7.21 (t, J = 8.2 Hz, 2H), 7.16 (d, J = 0.9 Hz, 1H), 7.13 – 7.07 (m, 3H), 7.03 – 7.00 (m, 3H), 4.62 (s, 1H), 4.35 (dd, J = 10.6, 1.9 Hz, 1H), 4.07 – 3.99 (m, 1H), 3.88 (dd, J = 11.9, 2.1 Hz, 1H), 2.81 (t, J = 11.1 Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.5, 148.2, 148.2, 143.5, 142.8, 141.4, 138.9, 137.7, 134.9, 133.9, 130.0 (2C), 129.7 (2C), 129.5, 129.0 (2C), 128.6 (2C), 128.4, 128.2, 127.9 (2C), 127.8 (2C), 127.7, 125.6, 123.7, 121.5, 114.9, 112.0, 64.7, 53.8, 49.8, 49.7, 41.1, 39.8. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 5.33$ min, $\tau_{\text{minor}} = 6.88$ min, (> 99:1 er). $[\alpha]_D^{21} = +81.3$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{37}\text{H}_{27}\text{N}_2\text{O}^+$: 515.2118; found: 515.2116.

(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,10-bis(4-methoxyphenyl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3b**



Following the general procedure product **3b** (17:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 60% yield (34.3 mg) as yellow solid; mp = 194 °C. ¹H NMR (700 MHz, CDCl₃) δ 9.34 (s, 1H), 7.50 – 7.45 (m, 2H), 7.26 – 7.23 (m, 2H), 7.22 – 7.16 (m, 4H), 7.15 – 7.08 (m, 6H), 7.07 – 7.02 (m, 3H), 6.98 – 6.93 (m, 2H), 4.58 (s, 1H), 4.29 (dd, *J* = 10.6, 2.1 Hz, 1H), 3.97 – 3.92 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.83 (dd, *J* = 11.9, 2.2 Hz, 1H), 2.75 (t, *J* = 11.0 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 190.6, 160.6, 159.7, 148.2, 148.1, 143.7, 142.7, 141.6, 139.1, 134.1, 131.2 (2C), 129.4, 128.9 (2C), 128.6 (2C), 128.2, 128.0 (2C), 127.7, 126.9, 125.5, 123.7, 121.5, 115.0 (2C), 114.9, 114.3 (2C), 112.2, 65.0, 55.6, 55.5, 53.9, 49.2, 49.0, 41.3, 39.8. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO₂ up to 40%; *i*-PrOH, flow rate = 2.2 mL/min τ_{major} = 7.10 min, τ_{minor} = 4.94 min, (> 99:1 er). [α]_D²¹ = + 45.2 (c = 1.0, CHCl₃). HRMS (ESI) m/z [M+H]⁺ Calcd. for C₃₉H₃₁N₂O₃: 575.2329; found: 575.2313.


3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,10-bis(3-methoxyphenyl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3c**



Following the general procedure product **3c** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 44% yield (25.2 mg) as yellow solid; mp = 170 °C. ¹H NMR (700 MHz, CDCl₃) δ 9.35 (s, 1H), 7.49 (dd, *J* = 8.3, 7.5 Hz, 1H), 7.35 (t, *J* = 8.0 Hz, 1H), 7.26 – 7.19 (m, 3H), 7.17 – 7.15 (m, 2H), 7.14 – 7.10 (m, 3H), 7.09 – 7.04 (m, 4H), 7.01 (dddd, *J* = 9.5, 8.4, 2.5, 0.9 Hz, 2H), 6.85 – 6.81 (m, 2H), 4.59 – 4.56 (m, 1H), 4.34 (dd, *J* = 10.6, 2.4 Hz, 1H), 3.97 (tt, *J* = 11.7, 2.0 Hz, 1H), 3.92 (s, 3H), 3.90 (dd, *J* = 11.9, 2.4 Hz, 1H), 3.84 (s, 3H), 2.76 (t, *J* = 11.1 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 190.5, 160.6, 160.0, 148.3, 148.2, 143.6, 142.9, 141.4, 139.4, 138.9, 136.4, 134.0, 130.7, 130.0, 128.6 (2C), 128.2, 127.9 (2C), 127.7, 125.6, 123.8, 122.2, 121.5, 120.0, 116.3, 114.9, 114.6, 114.2, 113.1, 112.0, 64.6, 55.6, 55.5, 53.8, 49.8, 49.7, 41.1, 39.9. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO₂ up to 40%; *i*-PrOH, flow


rate = 2.2 mL/min $\tau_{\text{major}} = 6.21$ min, $\tau_{\text{minor}} = 5.51$ min, ($> 99:1$ er). $[\alpha]_D^{21} = + 167.1$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{39}\text{H}_{30}\text{N}_2\text{O}_3^+$: 575.2329; found: 575.2334.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-5-phenyl-3,10-di-*p*-tolyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3d



Following the general procedure product **3d** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 59% yield (31.8 mg) as yellow solid; mp = 217 °C. ¹H NMR (700 MHz, CDCl_3) δ 9.34 (s, 1H), 7.46 (d, $J = 8.1$ Hz, 2H), 7.38 (d, $J = 7.7$ Hz, 2H), 7.25 – 7.19 (m, 4H), 7.18 – 7.12 (m, 4H), 7.12 – 7.06 (m, 3H), 7.06 – 7.01 (m, 3H), 4.59 (s, 1H), 4.33 (dd, $J = 10.6, 2.1$ Hz, 1H), 3.97 (tt, $J = 11.6, 1.9$ Hz, 1H), 3.87 (dd, $J = 12.0, 2.2$ Hz, 1H), 2.77 (t, $J = 11.0$ Hz, 1H), 2.49 (s, 3H), 2.44 (s, 3H). ¹³C NMR (176 MHz, CDCl_3) δ 190.6, 148.2, 148.2, 143.7, 142.6, 141.7, 139.6, 139.0, 138.2, 134.6, 134.1, 132.0, 130.3 (2C), 129.9 (2C), 129.7 (2C), 128.5 (2C), 128.1, 128.0 (2C), 127.7 (2C), 127.7, 125.5, 123.7, 121.4, 115.0, 112.1, 64.8, 53.9, 49.5, 49.4, 41.2, 39.8, 21.4, 21.3. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 4.79$ min, $\tau_{\text{minor}} = 4.17$ min, ($> 99:1$ er). $[\alpha]_D^{21} = + 100.1$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{39}\text{H}_{31}\text{N}_2\text{O}^+$: 543.2431; found: 543.2445.


(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-3,10-bis(4-chlorophenyl)-2-formyl-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3e



Following the general procedure product **3e** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 55% yield (32.1 mg) as brown solid; mp = 188 °C. ¹H NMR (700 MHz, CDCl_3) δ 9.35 (s, 1H), 7.56 (d, $J = 8.6$ Hz, 2H), 7.50 (d, $J = 8.5$ Hz, 2H), 7.42 (d, $J = 8.6$ Hz, 2H), 7.30-7.26 (m, 1H), 7.26-7.10 (m, 8H), 7.04-7.00 (m, 3H), 4.58 (s, 1H), 4.29 (dd, $J = 10.6, 1.9$ Hz, 1H), 4.02 – 3.91 (m, 1H), 3.76 (dd, $J = 11.9, 2.2$ Hz, 1H), 2.78 (t, $J = 11.1$ Hz, 1H). ¹³C NMR (176 MHz, CDCl_3) δ 190.1, 149.0, 148.0, 143.4, 143.1, 140.5, 138.7, 136.0, 135.8, 134.3, 133.7, 133.3, 131.1 (2C), 129.8 (2C), 129.1 (2C), 129.0 (2C), 128.6 (2C), 128.3, 127.8, 127.7 (2C), 125.7, 123.5, 121.6, 114.5, 111.7, 64.61, 53.6, 49.0, 49.0, 40.9, 39.7. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min τ_{major}


$\tau_{\text{minor}} = 5.54$ min, $\tau_{\text{minor}} = 4.89$ min, ($> 99:1$ er). $[\alpha]_D^{21} = +85.0$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{37}\text{H}_{25}\text{Cl}_2\text{N}_2\text{O}^+$: 583.1338; found: 583.1343.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-5-phenyl-3,10-bis(4-(trifluoromethyl)phenyl)-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-a]indene-4,4(3*H*)-dicarbonitrile 3f



Following the general procedure product **3f** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 36% yield (23.1 mg) as yellow solid; mp = 200 °C. ¹H NMR (700 MHz, CDCl_3) δ 9.37 (s, 1H), 7.86 (d, $J = 8.0$ Hz, 2H), 7.71 (dd, $J = 8.0, 3.1$ Hz, 4H), 7.41 (d, $J = 8.1$ Hz, 2H), 7.30 – 7.26 (m, 1H), 7.25 – 7.20 (m, 1H), 7.19 (d, $J = 7.6$ Hz, 1H), 7.17 (d, $J = 1.0$ Hz, 1H), 7.14 (td, $J = 7.5, 0.9$ Hz, 1H), 7.10 (t, $J = 7.8$ Hz, 2H), 6.99 (dd, $J = 14.9, 7.2$ Hz, 3H), 4.66 (s, 1H), 4.35 (dd, $J = 10.6, 2.1$ Hz, 1H), 4.06 (tt, $J = 11.8, 2.0$ Hz, 1H), 3.78 (dd, $J = 11.9, 2.2$ Hz, 1H), 2.88 (t, $J = 11.2$ Hz, 1H). ¹³C NMR (176 MHz, CDCl_3) δ 190.1, 148.2, 148.1, 144.0, 143.0, 141.8, 140.1, 138.8, 138.7, 133.6, 131.9 (q, $J = 32.7$ Hz), 131.0 (q, $J = 32.9$ Hz), 130.4 (2C), 128.7 (2C), 128.6, 128.3 (2C), 128.1, 127.7 (2C), 126.8 (q, $J = 3.5$ Hz, 2C), 126.0, 126.0 (q, $J = 3.7$ Hz, 2C), 124.1 (q, $J = 272.1$ Hz), 123.9 (q, $J = 272.2$ Hz), 123.6, 121.9, 114.4, 111.6, 64.6, 53.7, 49.5, 49.3, 41.0, 39.9. ¹⁹F NMR (376 MHz CDCl_3) δ -62.44, -62.64. The er was determined by UPC² using a chiral Chiralpack IA column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 3.08$ min, $\tau_{\text{minor}} = 2.89$ min, ($> 99:1$ er). $[\alpha]_D^{21} = +78.6$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{39}\text{H}_{25}\text{F}_6\text{N}_2\text{O}^+$: 651.1865; found: 651.1859.


(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-3,10-di(naphthalen-2-yl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydronaphthaleno[2,1-a]indene-4,4(3*H*)-dicarbonitrile 3g



Following the general procedure product **3g** (>20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 50% yield (30.7 mg) as yellow solid; mp = 190 °C. ¹H NMR (700 MHz, CDCl_3) δ 9.36 (s, 1H), 8.10 (d, $J = 8.5$ Hz, 1H), 8.06 – 8.04 (m, 1H), 8.01 – 7.96 (m, 2H), 7.95 – 7.92 (m, 2H), 7.90 – 7.85 (m, 1H), 7.75 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.68 – 7.66 (m, 1H), 7.65 – 7.56 (m, 4H), 7.47 (dd, $J = 8.5, 2.0$ Hz, 1H), 7.25 – 7.22 (m, 2H), 7.18 (dt, $J = 7.6, 1.0$ Hz, 1H), 7.07 (td, $J = 7.4, 1.2$ Hz, 1H), 6.98 (ddt, $J = 16.4, 7.6, 1.0$ Hz, 2H), 6.92 (dt, $J = 6.7, 1.3$ Hz, 2H), 6.66 – 6.62 (m, 2H), 4.83 – 4.79 (m, 1H), 4.50 (dd, $J = 10.6, 2.4$ Hz, 1H), 4.19 (tt, $J = 11.7, 2.1$ Hz, 1H), 4.11 (dd,


J = 11.9, 2.3 Hz, 1H), 3.04 (t, *J* = 11.0 Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.5, 148.4, 148.1, 143.6, 143.1, 141.4, 139.1, 135.2, 133.9, 133.8, 133.7, 133.4, 133.0, 132.7, 129.6, 129.0, 128.8, 128.3 (2C), 128.2, 128.1, 128.0, 127.9 (2C), 127.8, 127.7 (2C), 127.3, 127.2, 127.0 (2C), 126.6, 125.7, 125.3, 123.8, 121.5, 115.0, 112.0, 64.8, 53.9, 50.1, 50.0, 41.1, 40.0. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; ACN flow rate = 2.2 mL/min $\tau_{\text{major}} = 5.91$ min, $\tau_{\text{minor}} = 5.40$ min, (> 99:1 er). $[\alpha]_D^{21} = -16.7$ (*c* = 1.0, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{45}\text{H}_{30}\text{N}_2\text{O}_6^+$: 615.2431; found: 615.2440.

(3*S*,4*aS*,9*bR*,10*R*,10*aS*)-2-formyl-3,10-di(furan-2-yl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3h



Following the general procedure product **3h** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 52% yield (25.6 mg) as yellow solid; mp = 174 °C. ^1H NMR (700 MHz, CDCl_3) δ 9.40 (s, 1H), 7.61 (dt, *J* = 1.9, 1.0 Hz, 1H), 7.46 (dd, *J* = 1.9, 1.0 Hz, 1H), 7.34 – 7.27 (m, 5H), 7.28 – 7.17 (m, 5H), 6.55 (dd, *J* = 3.2, 1.9 Hz, 1H), 6.51 (d, *J* = 3.2 Hz, 1H), 6.46 (dd, *J* = 3.3, 1.9 Hz, 1H), 6.43 (dd, *J* = 3.4, 1.0 Hz, 1H), 4.72 (d, *J* = 1.6 Hz, 1H), 4.42 (dd, *J* = 10.7, 2.3 Hz, 1H), 4.05 (dd, *J* = 11.9, 2.3 Hz, 1H), 3.97 (tt, *J* = 12.1, 2.1 Hz, 1H), 2.95 (t, *J* = 10.9 Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.2, 152.0, 148.6, 148.3, 148.1, 143.7, 143.4, 143.3, 143.1, 141.0, 136.8, 134.1, 128.8 (2C), 128.4, 128.0 (2C), 127.9, 125.8, 123.9, 121.6, 114.1, 112.4, 111.7, 111.4, 111.0, 108.0, 62.4, 52.2, 43.8, 42.8, 41.3, 40.5. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 4.03$ min, $\tau_{\text{minor}} = 4.25$ min, (> 99:1 er). $[\alpha]_D^{21} = +58.2$ (*c* = 1.0, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{33}\text{H}_{23}\text{N}_2\text{O}_3^+$: 495.1703; found: 495.1716.


(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-7-methoxy-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3i



Following the general procedure product **3i** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 53% yield (28.8 mg) as yellow solid; mp = 170 °C. ^1H NMR (700 MHz, CDCl_3) δ 9.35 (s, 1H), 7.58 – 7.54 (m, 4H), 7.50 – 7.46 (m, 2H), 7.44 (t, *J* = 7.3 Hz, 2H), 7.28 (d, *J* = 7.3 Hz, 2H), 7.22 – 7.18 (m, 1H), 7.15 (d, *J* = 1.1 Hz, 1H), 7.09 (t, *J* = 7.7 Hz, 2H), 7.00 (d, *J* = 7.0 Hz, 2H), 6.91 (d, *J* = 8.3 Hz, 1H), 6.72 (t, *J* = 2.9 Hz, 1H), 6.66 (dd, *J* = 8.3, 2.4 Hz, 1H), 4.61 (s, 1H), 4.29 (dd, *J* = 10.6, 1.9 Hz, 1H), 3.99 (tt, *J* = 11.8, 2.0 Hz, 1H), 3.86 (dd,


J = 11.9, 2.1 Hz, 1H), 3.71 (s, 3H), 2.76 (t, *J* = 11.2 Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.5, 160.0, 149.7, 148.3, 142.8, 142.7, 138.9, 137.8, 135.8, 134.9, 133.9, 130.0 (2C), 129.7 (2C), 129.5, 129.0 (2C), 128.7 (2C), 128.4, 128.2, 127.8 (2C), 127.8 (2C), 124.3, 114.9, 112.0, 111.7, 107.0, 64.2, 55.6, 53.6, 50.0, 49.8, 41.1, 39.8. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min τ_{major} = 5.39. min, τ_{minor} = 6.61 min, (>99:1 er). $[\alpha]_D^{21} = +124.6$ (*c* = 1.0, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{38}\text{H}_{29}\text{N}_2\text{O}_2^+$: 545.2223; found: 545.2211.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-8-methoxy-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3j



Following the general procedure product **3j** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 47% yield (25.6 mg) as yellow solid; mp = 162 °C. ^1H NMR (700 MHz, CDCl_3) δ 9.35 (s, 1H), 7.59 – 7.54 (m, 4H), 7.53 – 7.38 (m, 4H), 7.28 (d, *J* = 7.2 Hz, 2H), 7.22 – 7.17 (m, 1H), 7.15 (d, *J* = 1.1 Hz, 1H), 7.09 (dd, *J* = 12.1, 5.0 Hz, 3H), 7.01 (dd, *J* = 7.9, 1.0 Hz, 2H), 6.79 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.58 (d, *J* = 2.3 Hz, 1H), 4.61 (s, 1H), 4.29 (dd, *J* = 10.6, 2.0 Hz, 1H), 3.99 (tt, *J* = 11.7, 2.0 Hz, 1H), 3.86 (dd, *J* = 11.9, 2.4 Hz, 1H), 3.70 (s, 3H), 2.80 (t, *J* = 11.3 Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.5, 158.4, 148.3, 145.4, 142.7, 141.3, 139.0, 138.8, 137.6, 134.9, 134.2, 130.0 (2C), 129.7 (2C), 129.5, 129.0 (2C), 128.6 (2C), 128.4, 128.1, 127.9 (2C), 127.8 (2C), 122.0, 115.0, 112.6, 112.1, 110.8, 64.5, 55.6, 53.8, 49.8 (2C), 41.3, 39.8. The er was determined by UPC² using a chiral Chiralpack IC column gradient from 100% CO_2 up to 40%; ACN, flow rate = 2.2 mL/min τ_{major} = 4.91 min, τ_{minor} = 4.59 min, (> 99:1 er). $[\alpha]_D^{21} = +49.5$ (*c* = 1.0, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{38}\text{H}_{29}\text{N}_2\text{O}_2^+$: 545.2223; found: 545.2206.


(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-7-methyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3k



Following the general procedure product **3k** (>20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 54% yield (28.5 mg) as yellow solid; mp = 175 °C. NMR (700 MHz, CDCl_3) δ 9.35 (s, 1H), δ 7.61 – 7.54 (m, 4H), 7.52 – 7.40 (m, 4H), 7.30 – 7.27 (m, 2H), 7.25 – 7.18 (m, 1H), 7.16 – 7.14 (m, 1H), 7.10 (t, *J* = 7.7 Hz, 2H), 7.04 – 6.98 (m, 3H), 6.95 – 6.87 (m, 2H), 4.61 (s, 1H), 4.31 (dd, *J* = 10.6, 1.9 Hz, 1H), 4.00 (tt, *J* = 11.7, 1.9 Hz, 1H),


3.86 (dd, $J = 12.0, 2.2$ Hz, 1H), 2.77 (t, $J = 11.0$ Hz, 1H), 2.29 (s, 3H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.5, 148.4, 148.3, 142.9, 141.6, 140.7, 138.9, 137.8, 137.7, 134.9, 134.1, 130.0 (2C), 129.6 (2C), 129.5, 129.0 (2C), 128.6 (2C), 128.4, 128.1, 127.9 (4C), 126.4, 123.4, 122.1, 114.9, 112.0, 64.5, 53.7, 49.9, 49.8, 41.2, 39.8, 21.6. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 5.23$ min, $\tau_{\text{minor}} = 6.72$ min, (> 99:1 er). $[\alpha]_D^{21} = -46.5$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{38}\text{H}_{29}\text{N}_2\text{O}^+$: 529.2274; found: 529.2265.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-8-bromo-2-formyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3l



Following the general procedure product **3l** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 40% yield (23.7 mg) as yellow solid; mp = 169 °C. ^1H NMR (700 MHz, CDCl_3) δ 9.35 (s, 1H), 7.61 – 7.58 (m, 2H), 7.56 – 7.54 (m, 2H), 7.53 – 7.50 (m, 1H), 7.50 – 7.46 (m, 1H), 7.46 – 7.43 (m, 2H), 7.38 (dd, $J = 8.1, 1.9$ Hz, 1H), 7.29 – 7.26 (m, 2H), 7.21 (tt, $J = 7.5, 1.3$ Hz, 1H), 7.14 – 7.11 (m, 2H), 7.11 – 7.07 (m, 2H), 7.04 (d, $J = 8.1$ Hz, 1H), 6.99 – 6.97 (m, 2H), 4.61 (s, 1H), 4.33 (dd, $J = 10.7, 2.4$ Hz, 1H), 3.97 (tt, $J = 11.8, 2.1$ Hz, 1H), 3.85 (dd, $J = 12.0, 2.4$ Hz, 1H), 2.82 (t, $J = 11.2$ Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.4, 147.8, 147.1, 145.4, 142.2, 141.9, 139.0, 137.1, 134.8, 133.4, 130.9, 130.0 (2C), 129.9 (2C), 129.6, 129.1 (2C), 128.7 (2C), 128.7, 128.4, 127.8 (4C), 126.9, 122.8, 120.1, 114.8, 111.9, 64.3, 53.9, 49.8, 49.5, 41.0, 39.8. The er was determined by UPC² using a chiral Chiralpack IC column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 5.70$ min, $\tau_{\text{minor}} = 5.34$ min, (99:1 er). $[\alpha]_D^{21} = +30.9$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{37}\text{H}_{26}\text{BrN}_2\text{O}^+$: 593.1223; found: 593.1204.


(3*S*,4*aS*,9*bS*,10*R*,10*aR*)-9-bromo-2-formyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3m



Following the general procedure product **3m** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 30% yield (17.8 mg) as yellow solid; mp = 210 °C. ^1H NMR (700 MHz, CDCl_3) δ 9.30 (s, 1H), 7.79 (s, 1H), 7.60 – 7.55 (m, 1H), 7.49 – 7.41 (m, 5H), 7.35 – 7.30 (m, 1H), 7.28 (dd, $J = 5.2, 3.6$ Hz, 2H), 7.25 (d, $J = 1.8$ Hz, 1H), 7.21 (tt, $J = 7.5, 1.3$ Hz, 1H), 7.12 – 7.07 (m, 4H), 7.01 – 6.98 (m, 3H), 4.59 (s, 1H), 4.49 (dd, $J = 10.0, 2.3$ Hz, 1H),


4.06 (tt, $J = 11.9$, 2.1 Hz, 1H), 3.83 (dd, $J = 12.3$, 2.3 Hz, 1H), 2.84 (dd, $J = 11.8$, 10.1 Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.40, 149.93, 148.11, 143.42, 143.06, 142.34, 138.96, 138.68, 134.88, 133.38, 130.21, 130.01 (2C), 129.52, 129.37 (4C), 129.01 (2C), 128.73 (2C), 128.44, 128.41, 127.87 (2C), 126.30, 120.33, 119.29, 114.79, 111.83, 66.43, 54.66, 50.56, 49.77, 41.17, 39.00. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 4.43$ min, $\tau_{\text{minor}} = 6.50$ min, (> 99:1 er). $[\alpha]_D^{21} = + 99.5$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{37}\text{H}_{26}\text{BrN}_2\text{O}^+$: 593.1223; found: 593.1217.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-5-(4-methoxyphenyl)-3,10-diphenyl-4*a*,9*b*,10,10a**-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3n**




Following the general procedure product **3n** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 46% yield (25.1 mg) as yellow solid; mp = 173 °C. ^1H NMR (700 MHz, CDCl_3) δ 9.35 (s, 1H), 7.59 – 7.54 (m, 4H), 7.47 – 7.44 (m, 2H), 7.45 (dd, $J = 11.4$, 4.5 Hz, 2H), 7.29 (d, $J = 7.2$ Hz, 2H), 7.25 – 7.24 (m, 1H), 7.21 (d, $J = 7.6$ Hz, 1H), 7.16 (d, $J = 1.2$ Hz, 1H), 7.10 (td, $J = 7.4$, 1.1 Hz, 1H), 7.00 (d, $J = 7.5$ Hz, 1H), 6.94 – 6.91 (m, 2H), 6.60 (t, $J = 5.7$ Hz, 2H), 4.63 (s, 1H), 4.33 (dd, $J = 10.6$, 2.2 Hz, 1H), 4.01 (tt, $J = 11.8$, 2.0 Hz, 1H), 3.85 (dd, $J = 11.9$, 2.3 Hz, 1H), 3.73 (s, 3H), 2.78 (t, $J = 11.1$ Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.5, 159.4, 148.4 (2C), 143.6, 142.6, 141.1, 139.0, 137.8, 134.9, 130.1 (2C), 129.7 (2C), 129.5, 129.0 (2C), 129.0 (2C), 128.4, 127.9 (2C), 127.7, 126.2, 125.5, 123.7, 121.5, 115.0, 114.1 (2C), 112.1, 64.7, 55.3, 53.9, 49.8, 49.8, 41.2, 39.8. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO_2 up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 5.38$ min, $\tau_{\text{minor}} = 6.61$ min, (> 99:1 er). $[\alpha]_D^{21} = -39.6$ ($c = 1.0$, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{38}\text{H}_{29}\text{N}_2\text{O}_2^+$: 545.2223; found: 545.2211.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-5-(4-fluorophenyl)-2-formyl-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3o



Following the general procedure product **3o** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 56% yield (29.8 mg) as yellow solid; mp = 176 °C. ¹H NMR (700 MHz, CDCl₃) δ 9.35 (s, 1H), 7.60 – 7.55 (m, 4H), 7.52 – 7.48 (m, 2H), 7.45 (t, J = 7.4 Hz, 2H), 7.27 (t, J = 7.1 Hz, 3H), 7.15 (d, J = 7.6 Hz, 2H), 7.12 (td, J = 7.5, 0.9 Hz, 1H), 7.01 (d, J = 7.4 Hz, 1H), 6.98 (dd, J = 8.4, 5.3 Hz, 2H), 6.78 (t, J = 8.7 Hz, 2H), 4.63 (s, 1H), 4.34 (dd, J = 10.6, 2.1 Hz, 1H), 4.01 (tt, J = 11.7, 2.0 Hz, 1H), 3.81 (dd, J = 11.9, 2.3 Hz, 1H), 2.82 – 2.78 (m, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 190.4, 162.6 (d, J = 247.4 Hz), 148.1, 148.1, 143.5, 141.9, 141.9, 138.9, 137.6, 134.8, 130.0 (2C), 129.9 (d, J = 3.4 Hz), 129.7 (2C), 129.6 (d, J = 8.2 Hz, 2C), 129.6, 129.0 (2C), 128.5, 127.9 (2C), 127.8, 125.8, 123.8, 121.3, 115.7 (d, J = 21.6 Hz, 2C), 114.8, 112.2, 64.8, 53.8, 49.7, 49.7, 41.1, 39.9. ¹⁹F NMR (376 MHz, CDCl₃) δ -113.0. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO₂ up to 40%; *i*-PrOH, flow rate = 2.2 mL/min τ_{major} = 5.13 min, τ_{minor} = 6.12 min, (> 99:1 er). [α]_D²¹ = -19.5 (c = 1.0, CHCl₃). HRMS (ESI) m/z [M+H]⁺ Calcd. for C₃₇H₂₆FN₂O⁺: 533.2024; found: 533.2017.


(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-5-([1,1'-biphenyl]-4-yl)-2-formyl-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3p



Following the general procedure product **3p** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 49% yield (28.9 mg) as yellow solid; mp = 226 °C. ¹H NMR (700 MHz, CDCl₃) δ 9.36 (s, 1H), 7.58 (d, J = 4.5 Hz, 4H), 7.52 – 7.49 (m, 4H), 7.48 – 7.45 (m, 2H), 7.45 – 7.41 (m, 2H), 7.34 (ddt, J = 7.8, 6.9, 1.3 Hz, 1H), 7.32 – 7.29 (m, 4H), 7.28 – 7.26 (m, 2H), 7.17 (dd, J = 2.3, 1.1 Hz, 1H), 7.14 – 7.10 (m, 1H), 7.09 – 7.07 (m, 2H), 7.05 – 7.01 (m, 1H), 4.64 (s, 1H), 4.37 (dd, J = 10.7, 2.9 Hz, 1H), 4.04 (tt, J = 11.8, 2.1 Hz, 1H), 3.90 (dd, J = 11.9, 2.4 Hz, 1H), 2.82 (dd, J = 11.7, 10.6 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 190.49, 148.33, 148.12, 143.62, 142.64, 141.65, 140.99, 140.94, 138.98, 137.70, 134.91, 132.83, 130.13 (2C), 129.68 (2C), 129.52, 129.02 (2C), 128.81 (2C), 128.45, 128.25 (2C), 127.89 (2C), 127.78, 127.42, 127.34 (2C), 127.23 (2C), 125.66, 123.76, 121.55, 114.98, 112.07, 64.81, 53.92, 49.83, 49.80, 41.23, 39.86. The er was determined by UPC² using a chiral Chiralpack IA


column gradient from 100% CO₂ up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 4.50$. min, $\tau_{\text{minor}} = 4.28$ min, (> 99:1 er). $[\alpha]_D^{21} = + 96.2$ (*c* = 1.0, CHCl₃). HRMS (ESI) m/z [M+H]⁺ Calcd. for C₄₃H₃₁N₂O⁺: 591.2431; found: 591.2429.

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-5-(5-methylthiophen-2-yl)-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3q



Following the general procedure product **3q** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 47% yield (25.1 mg) as orange solid; mp = 148 °C. ¹H NMR (700 MHz, CDCl₃) δ 9.36 (s, 1H), 7.57 – 7.53 (m, 4H), 7.50 – 7.44 (m, 4H), 7.43 (dt, *J* = 7.7, 0.9 Hz, 1H), 7.36 – 7.32 (m, 2H), 7.29 (td, *J* = 7.6, 1.4 Hz, 1H), 7.16 (dd, *J* = 2.3, 1.1 Hz, 1H), 7.11 (td, *J* = 7.5, 1.1 Hz, 1H), 6.98 (dq, *J* = 7.6, 1.0 Hz, 1H), 6.66 (d, *J* = 3.4 Hz, 1H), 6.54 (dq, *J* = 3.3, 1.1 Hz, 1H), 4.67 (s, 1H), 4.32 (dd, *J* = 10.6, 2.4 Hz, 1H), 4.04 (tt, *J* = 11.8, 2.1 Hz, 1H), 3.85 (dd, *J* = 11.9, 2.4 Hz, 1H), 2.77 (dd, *J* = 11.7, 10.5 Hz, 1H), 2.28 (d, *J* = 1.1 Hz, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 190.5, 148.4, 147.6, 143.5, 143.3, 140.4, 139.0, 137.6, 137.1, 134.8, 131.5, 130.3 (2C), 129.7 (2C), 129.4, 129.1 (2C), 128.4, 127.9 (2C), 127.8, 127.2, 125.8, 125.5, 123.8, 121.6, 115.1, 112.0, 64.6, 54.0, 49.9, 49.8, 41.5, 40.0, 15.0. The er was determined by UPC² using a chiral Chiralpack IB column gradient from 100% CO₂ up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 5.35$. min, $\tau_{\text{minor}} = 6.85$ min, (> 99:1 er). $[\alpha]_D^{21} = + 125.0$ (*c* = 1.0, CHCl₃). HRMS (ESI) m/z [M+H]⁺ Calcd. for C₃₆H₂₇N₂O⁺: 535.1839; found: 535.1836.


(3*S*,4*aS*,9*bS*,10*R*,10*aR*)-2-formyl-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3r



Following the general procedure product **3r** (20:1 dr in a crude reaction mixture) was isolated as a single diastereoisomer in 56% yield (24.6 mg) as yellow solid; mp = 158 °C. ¹H NMR (700 MHz, CDCl₃) δ 9.33 (s, 1H), 7.59 – 7.52 (m, 4H), 7.50 – 7.46 (m, 1H), 7.45 – 7.39 (m, 3H), 7.35 (d, *J* = 7.6 Hz, 1H), 7.30 – 7.26 (m, 3H), 7.12 (dd, *J* = 2.3, 1.3 Hz, 1H), 7.07 (td, *J* = 7.4, 1.2 Hz, 1H), 7.00 (dt, *J* = 7.6, 1.0 Hz, 1H), 6.93 (t, *J* = 2.4 Hz, 1H), 4.70 (s, 1H), 4.24 (dt, *J* = 10.9, 2.6 Hz, 1H), 3.77 (tt, *J* = 11.8, 2.1 Hz, 1H), 3.32 (dt, *J* = 12.2, 2.4 Hz, 1H), 2.78 (t, *J* = 11.1 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 190.5, 147.7, 147.6, 146.8, 143.8, 139.1, 137.6, 135.2, 129.9, 129.8 (2C), 129.7, 129.7 (2C), 129.3 (2C), 128.4, 127.8, 127.8 (2C), 125.3, 123.7, 122.4, 114.4, 113.2, 65.6, 52.4, 49.4, 48.9, 41.3, 40.9. The er was determined by UPC² using a chiral Chiralpack IB column

gradient from 100% CO₂ up to 40%; *i*-PrOH, flow rate = 2.2 mL/min $\tau_{\text{major}} = 4.82$ min, $\tau_{\text{minor}} = 5.41$ min, (> 99:1 er). $[\alpha]_D^{21} = + 83.3$ (c = 1.0, CHCl₃). HRMS (ESI) m/z [M+Na]⁺ Calcd. for C₃₁H₂₂N₂ONa⁺: 461.1625; found: 461.1618.


4. Enantioselective synthesis of (*3S,4aS,9bR,10R,10aR*)-2-formyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(*3H*)-dicarbonitrile **3a on a 1 mmol scale**



In an ordinary 8 mL glass vial equipped with a magnetic stirring, malononitrile **1a** (1 mmol), α,β -unsaturated aldehyde **2a** (1 mmol) and *R*-mandelic acid (0.4 mmol) were dissolved in DCE (4 mL) and catalyst **4a** (66 mg, 0.2 mmol) was added. The reaction mixture was stirred in room temperature for 24h. After this time, the reaction mixture was directly subjected to column chromatography on silica gel (hexanes: ethyl acetate 80:20) to afford pure product **3a**.


5. Selective transformations of products 3

5.1. Selective reduction of aldehyde 3a




In an ordinary 4 mL glass vial equipped with a magnetic stirring bar, the aldehyde **3a** (0.1 mmol, 1.0 equiv.) and CeCl₃·7H₂O (0.1 mmol, 1.0 equiv.) were dissolved in the mixture of CH₂Cl₂ (0.2 mL) and MeOH (0.2 mL). Then NaBH₄ (0.1 mmol, 1.0 equiv.) was added to the cold reaction mixture and was stirred at room temperature for 30 minutes. After full conversion of the starting material **3a** (as confirmed by TLC analysis), the reaction mixture was directly subjected to column chromatography on silica gel (eluent: hexanes/ethyl acetate 80:20) to afford pure product **10a** in 94 % yield (48.5 mg) as light-yellow solid; mp = 152°C.

(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-(Hydroxymethyl)-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 10*a***




¹H NMR (700 MHz, CDCl₃) δ 7.55 – 7.51 (m, 4H), 7.51 – 7.46 (m, 3H), 7.44 (ddd, *J* = 8.5, 6.3, 2.2 Hz, 1H), 7.36 (d, *J* = 7.2 Hz, 2H), 7.24 (t, *J* = 7.4 Hz, 1H), 7.22 – 7.17 (m, 2H), 7.12 – 7.07 (m, 3H), 7.05 (d, *J* = 7.0 Hz, 2H), 7.00 (d, *J* = 7.5 Hz, 1H), 6.19 (s, 1H), 4.31 (dd, *J* = 10.6, 1.9 Hz, 1H), 4.27 (s, 1H), 3.87 (dd, *J* = 12.9, 3.7 Hz, 1H), 3.82 (dt, *J* = 11.8, 7.6 Hz, 2H), 3.73 (dd, *J* = 11.8, 2.0 Hz, 1H), 2.66 (t, *J* = 11.1 Hz, 1H), 1.37 (dd, *J* = 6.8, 5.1 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ 148.4, 143.8, 143.2, 141.9, 138.6, 135.9, 135.1, 134.3, 130.6 (2C), 129.5, 129.4 (2C), 129.1 (2C), 128.5 (2C), 128.0 (2C), 128.0, 127.9 (3C), 127.5, 125.9, 125.3, 123.7, 121.3, 115.5, 112.6, 64.8, 64.7, 52.6 (2C), 50.2, 41.6, 40.1. [α]_D²¹ = + 115.0 (c = 1.0, CHCl₃). HRMS (ESI) m/z [M+H]⁺ Calcd. for C₃₇H₂₉N₂O⁺: 517.2274; found: 517.2268.

5.2. Selective Suzuki coupling of aldehyde **3I**



In an ordinary 4 mL glass vial equipped with a magnetic stirring bar and a screw septum cap, the $\text{Pd}(\text{PPh}_3)_4$ (0.005 mmol, 0.05 equiv.) was placed. The vial was evacuated and filled with argon. Phenylboronic acid **11** (0.11 mmol, 1.1 equiv.) was dissolved in the mixture of PhCH_3 (0.4 mL) and EtOH (0.1 mL), the solution was degassed and then was added *via* syringe to the reaction vial. Aldehyde **3I** (0.1 mmol, 1.0 equiv.) was dissolved in the PhCH_3 (0.5 mL), the solution was degassed and then was added *via* syringe to the reaction vial. Then, degassed, aqueous solution of K_2CO_3 (2M, 50 μL) was added and the reaction mixture was stirred at 70 °C for 2h. After full conversion of the starting material **3I** (as confirmed by TLC analysis), the mixture was cooled to rt, quenched with brine (5 mL), extracted with CHCl_3 (3×5 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting solid was subjected to column chromatography on silica gel (eluent: hexanes/ethyl acetate 80:20) to afford pure product **12I** in 62 % yield (36.6 mg) as brown solid; mp = 160 °C.

(3S,4aS,9bR,10R,10aR)-2-formyl-3,5,8,10-tetraphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 12I



^1H NMR (700 MHz, CDCl_3) δ 9.36 (s, 1H), 7.61 – 7.57 (m, 4H), 7.53 – 7.47 (m, 3H), 7.48 – 7.44 (m, 4H), 7.41 – 7.38 (m, 2H), 7.33 – 7.29 (m, 3H), 7.27 (dd, J = 8.0, 0.6 Hz, 1H), 7.26 – 7.21 (m, 2H), 7.17 (dd, J = 2.2, 1.1 Hz, 1H), 7.12 (t, J = 7.8 Hz, 2H), 7.06 – 7.04 (m, 2H), 4.64 (s, 1H), 4.42 (dd, J = 10.6, 2.5 Hz, 1H), 4.04 (tt, J = 11.8, 2.0 Hz, 1H), 3.91 (dd, J = 12.0, 2.4 Hz, 1H), 2.88 (dd, J = 11.6, 10.6 Hz, 1H). ^{13}C NMR (176 MHz, CDCl_3) δ 190.4, 148.2, 147.4, 144.3, 142.7, 141.7, 141.2, 139.0, 138.9, 137.6, 134.9, 133.9, 130.0 (2C), 129.7 (2C), 129.5, 129.0 (2C), 128.9 (2C), 128.7 (2C), 128.5, 128.2, 127.8 (2C), 127.8 (2C), 127.3, 127.3 (2C), 127.0, 122.5, 121.7, 114.9, 112.0, 64.8, 53.8, 49.8, 49.7, 41.2, 39.9. $[\alpha]_D^{21} = +224.7$ (c = 1.0, CHCl_3). HRMS (ESI) m/z [M+H]⁺ Calcd. for $\text{C}_{46}\text{H}_{31}\text{N}_2\text{O}^+$: 591.2431; found: 591.2430.

6. Crystal and X-ray data for (*3S,4aS,9bS,10R,10aR*)-9-bromo-2-formyl-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3*H*)-dicarbonitrile **3m**

The crystal structure of the compound **3m**, $C_{37}H_{25}BrN_2O \cdot CHCl_3$, was established by single-crystal X-ray diffraction at 100 K. The compound crystallizes in the non-centrosymmetric orthorhombic space group $P2_12_12_1$ ($Z = 4$), with one crystallographically independent formula unit per unit cell (Figure 1).




Figure 1. The molecular structure of the compound **3m** at 100 K, showing 50% probability displacement ellipsoids. Hydrogen atoms are drawn with an arbitrary radius.

Single crystal X-ray diffraction data were collected at 100 K by the ω -scan technique using a RIGAKU XtaLAB Synergy, Dualflex, Pilatus 300K diffractometer³ with PhotonJet micro-focus X-ray Source Cu-K α ($\lambda = 1.54184$ Å). Data collection, cell refinement, data reduction and absorption correction were performed using CrysAlis PRO software.³ The crystal structure was

³ Rigaku OD. CrysAlis PRO. Rigaku Oxford Diffraction Ltd, Yarnton, Oxfordshire, England, 2019.

solved using direct methods and the SHELXT 2018/2 program,⁴ with atomic scattering factors taken from the International Tables for X-ray Crystallography. Positional parameters of non-H-atoms were refined by a full-matrix least-squares method on F² with anisotropic thermal parameters by using the SHELXL 2019/3 program.⁵ All hydrogen atoms were found from the difference Fourier maps and for further calculations they were positioned geometrically in calculated positions (C–H = 0.95–1.00 Å) and constrained to ride on their parent atoms with isotropic displacement parameters set to 1.2 times the U_{eq} of the parent atom.

3m: Formula C₃₈H₂₆Cl₃BrN₂O, orthorhombic, space group P2₁2₁2₁, Z = 4, unit cell constants *a* = 10.9432(1), *b* = 15.0034(1), *c* = 19.5901(1) Å, V = 3216.41(4) Å³. The integration of the data yielded a total of 117789 reflections with θ angles in the range of 3.71 to 67.73°, of which 5828 were unique (*R*_{int} = 2.54%). The final anisotropic full-matrix least-squares refinement on F² with 406 parameters. The final *R*₁ was 0.0181 (for I > 2σ(I)) and wR₂ was 0.0467 (all data). The largest peak in the final difference electron density synthesis was 0.279 eÅ⁻³ and the largest hole was -0.281 eÅ⁻³. The goodness-of-fit was 1.084. The absolute configuration was unambiguously established from anomalous scattering, by calculating the x Flack parameter⁶ of -0.0070(18) using 2538 quotients.

CCDC 2279932 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.


⁴ Sheldrick, G.M. "SHELXT - integrated space-group and crystal-structure determination", *Acta Cryst.* 2015, **A71**, 3-8.

⁵ Sheldrick, G.M. "Crystal structure refinement with SHELXL", *Acta Cryst.* 2015, **C71**, 3-8.


⁶ Parsons, S.; Flack, H.D.; Wagner, T. "Use of intensity quotients and differences in absolute structure refinement" *Acta Cryst.* 2013, **B69**, 249-259.

7. NMR spectra

**2-((3-phenyl-1*H*-inden-2-yl)methylene)malononitrile 1a
¹H NMR (700 MHz, CDCl₃)**




¹³C NMR (176 MHz, CDCl₃)




2-((5-methoxy-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile 1b

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




2-((6-methoxy-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile 1c

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




2-((5-methyl-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1d**

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




2-((6-bromo-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile 1e

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




2-((7-bromo-3-phenyl-1*H*-inden-2-yl)methylene)malononitrile **1f**

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




2-((3-(4-methoxyphenyl)-1*H*-inden-2-yl)methylene)malononitrile **1g**



¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)





2-((3-(4-fluorophenyl)-1*H*-inden-2-yl)methylene)malononitrile 1h
¹H NMR (700 MHz, CDCl₃)



^{19}F NMR (376 MHz, CDCl_3)




2-((3-([1,1'-biphenyl]-4-yl)-1*H*-inden-2-yl)methylene)malononitrile **1i**




2-((3-(5-methylthiophen-2-yl)-1*H*-inden-2-yl)methylene)malononitrile 1j

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




2-((1*H*-inden-2-yl)methylene)malononitrile **1k**

^1H NMR (700 MHz, CDCl_3)






^{13}C NMR (176 MHz, CDCl_3)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3*a***

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,10-bis(4-methoxyphenyl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3*b***

¹H NMR (700 MHz, CDCl₃)





¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,10-bis(3-methoxyphenyl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3c**

¹H NMR (700 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-5-phenyl-3,10-di-p-tolyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3d**

¹H NMR (700 MHz, CDCl₃)






¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-3,10-bis(4-chlorophenyl)-2-formyl-5-phenyl-4*a*,9*b*,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3e

¹H NMR (700 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-5-phenyl-3,10-bis(4-(trifluoromethyl)phenyl)-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3f**


¹H NMR (700 MHz, CDCl₃)



¹³C NMR (176 MHz, CDCl₃)






^{19}F NMR (376 MHz, CDCl_3)





(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-3,10-di(naphthalen-2-yl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3g

¹H NMR (700 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**S*)-2-formyl-3,10-di(furan-2-yl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3*h***

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-7-methoxy-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3i**

¹H NMR (700 MHz, CDCl₃)





¹³C NMR (176 MHz, CDCl₃)




(3S,4aS,9bR,10R,10aR)-2-formyl-8-methoxy-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3j

^1H NMR (700 MHz, CDCl_3)




¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-7-methyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroin-deno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3k**

¹H NMR (700 MHz, CDCl₃)




^{13}C NMR (176 MHz, CDCl_3)




(3S,4aS,9bR,10R,10aR)-8-bromo-2-formyl-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3l

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3S,4aS,9bS,10R,10aR)-9-bromo-2-formyl-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3m

^1H NMR (700 MHz, CDCl_3)




^{13}C NMR (176 MHz, CDCl_3)




(3S,4aS,9bR,10R,10aR)-2-formyl-5-(4-methoxyphenyl)-3,10-diphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3n

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3S,4aS,9bR,10R,10aR)-5-(4-fluorophenyl)-2-formyl-3,10-diphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3o


^1H NMR (700 MHz, CDCl_3)



^{13}C NMR (176 MHz, CDCl_3)




^{19}F NMR (376 MHz, CDCl_3)




(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-5-([1,1'-biphenyl]-4-yl)-2-formyl-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3p

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-5-(5-methylthiophen-2-yl)-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3q**

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3S,4aS,9bS,10R,10aR)-2-formyl-3,10-diphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3r

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-(hydroxymethyl)-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 10a**

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-3,5,8,10-tetraphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 12l

¹H NMR (700 MHz, CDCl₃)




¹³C NMR (176 MHz, CDCl₃)




8. UPC² data

(3*S*,4*a**S*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3a

Racemic sample




Enantiomerically enriched sample



Peak Results		
	RT	% Area
1	5.322	100.00


(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-3,10-bis(4-methoxyphenyl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3b

Racemic sample



Peak Results		
	RT	% Area
1	4.993	59.86
2	7.161	40.14


Enantiomerically enriched sample



Peak Results		
	RT	% Area
1	4.939	0.06
2	7.103	99.94


(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,10-bis(3-methoxyphenyl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3c**

Racemic sample



Peak Results		
	RT	% Area
1	5.511	43.94
2	6.207	56.06


Enantiomerically enriched sample




Peak Results

(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-5-phenyl-3,10-di-p-tolyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3d**


Racemic sample



Enantiomerically enriched sample




(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-3,10-bis(4-chlorophenyl)-2-formyl-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3e**
Racemic sample



Peak Results

	RT	% Area
1	4.894	39.97
2	5.541	60.03

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	4.886	0.06
2	5.534	99.94

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-2-formyl-5-phenyl-3,10-bis(4-(trifluoromethyl)phenyl)-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3*f*


Racemic sample



Peak Results

	RT	% Area
1	2.888	47.44
2	3.082	52.56

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	3.086	100.00

(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-3,10-di(naphthalen-2-yl)-5-phenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3g**


Racemic sample



Peak Results

	RT	% Area
1	5.403	35.83
2	5.907	64.17

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	5.786	100.00

(3S,4aS,9bR,10R,10aS)-2-formyl-3,10-di(furan-2-yl)-5-phenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3h


Racemic sample



Peak Results

	RT	% Area
1	4.031	55.59
2	4.253	44.41

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	4.034	100.00

(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-7-methoxy-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3i**


Racemic sample



Peak Results

	RT	% Area
1	5.384	42.53
2	6.607	57.47

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	5.485	100.00

(3S,4aS,9bR,10R,10aR)-2-formyl-8-methoxy-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3j


Racemic sample



Peak Results

	RT	% Area
1	4.585	45.08
2	4.911	54.92

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	4.909	100.00

(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-7-methyl-3,5,10-triphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3k**


Racemic sample



Peak Results

	RT	% Area
1	5.234	51.16
2	6.715	48.84

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	5.216	100.00

(3S,4aS,9bR,10R,10aR)-8-bromo-2-formyl-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3l


Racemic sample



Peak Results

	RT	% Area
1	5.336	36.06
2	5.695	63.94

Enantiomerically enriched sample




Peak Results


	RT	% Area
1	5.267	1.17
2	5.703	98.83

(3S,4aS,9bS,10R,10aR)-9-bromo-2-formyl-3,5,10-triphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3m

Racemic sample




Enantiomerically enriched sample



(3S,4aS,9bR,10R,10aR)-2-formyl-5-(4-methoxyphenyl)-3,10-diphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3n


Racemic sample



Peak Results

	RT	% Area
1	5.384	42.42
2	6.607	57.58

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	5.379	100.00

(3S,4aS,9bR,10R,10aR)-5-(4-fluorophenyl)-2-formyl-3,10-diphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3o


Racemic sample



Peak Results

	RT	% Area
1	5.127	55.99
2	6.122	44.01

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	5.128	100.00

(3*S*,4*aS*,9*bR*,10*R*,10*aR*)-5-([1,1'-biphenyl]-4-yl)-2-formyl-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3


Racemic sample



Peak Results

	RT	% Area
1	4.274	49.36
2	4.504	50.64

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	4.268	0.36
2	4.500	99.64

(3*S*,4*aS*,9*b**R*,10*R*,10*a**R*)-2-formyl-5-(5-methylthiophen-2-yl)-3,10-diphenyl-4*a*,9*b*,10,10*a*-tetrahydroindeno[2,1-*a*]indene-4,4(3*H*)-dicarbonitrile 3q**


Racemic sample



Peak Results

	RT	% Area
1	5.346	65.32
2	6.847	34.68

Enantiomerically enriched sample




Peak Results

	RT	% Area
1	5.348	100.00

(3S,4aS,9bS,10R,10aR)-2-formyl-3,10-diphenyl-4a,9b,10,10a-tetrahydroindeno[2,1-a]indene-4,4(3H)-dicarbonitrile 3r


Racemic sample



Peak Results

	RT	% Area
1	4.823	55.88
2	5.404	44.12

Enantiomerically enriched sample



Peak Results

	RT	% Area
1	4.821	100.00